On June 24, 2019 Shanghai Huaota Biopharmaceutical Co., Ltd. and Shanghai Junshi Biosciences Co., Ltd.-B (08177-HK) reported to have signed ‘Drug Technology Transfer and Cooperative Development Contract’ (Press release, Huabo Biopharm, JUN 24, 2019, View Source [SID1234656060]). According to the agreement, Junshi will acquire the existing results its follow-up technical support of Avastin monoclonal antibody biosimilar (project code "HOT-1010") and from Huaota for ￥90 million. After registration is successful, all the operating profits generated by the drug will be distributed equally to Junshi and Huaota. HOT-1010 is a recombinant humanized anti vascular endothelial growth factor (VEGF) monoclonal antibody injection and has acquired investigational new drug approval from the NMPA. HOT-1010 is now in phase I clinical study. HOT-1010 can selectively bind to human vascular endothelial growth factor (VEGF) and block its biological activity. It is mainly used to treat metastatic colorectal cancer and advanced, metastatic or recurrent non-small cell lung cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!